Current Biology, Volume 30

Supplemental Information

Disruption of EGF Feedback by Intestinal Tumors

and Neighboring Cells in Drosophila

Sang Ngo, Jackson Liang, Yu-Han Su, and Lucy Erin O'Brien



Figure S1. Analysis of *APC^{-/-}* clones in the adult *Drosophila* midgut. Related to Figure 1.

(A) Cell equilibrium in the *Drosophila* adult midgut arises through coupling of stem cell divisions to enterocyte apoptosis. (Left) In the absence of enterocyte apoptosis, stem cells lack essential EGF mitogens and are therefore quiescent. Healthy enterocytes do not secrete EGFs because enterocyte E-cad prevents p120-catenin and β -catenin from activating transcription of the obligate EGF protease *rhomboid*. (Right) During physiological apoptosis, enterocytes downregulate E-cad. Loss of E-cad enables p120- and β -catenin to activate transcription of *rhomboid*. Rhomboid cleaves EGFs for secretion; the secreted EGFs activate nearby stem cells for replacement divisions. Cartoon adapted from [S1].

(B) Midgut regions R4 and R5 were used for clonal analyses. (Left) Brightfield image of whole mount midgut. The R4-R5 regions [S2] are demarcated by red lines. (Right) 3D reconstruction of R4 and R5 regions from a midgut that contains 21-day, GFP-labeled, *APC*^{-/-} clones (green). Clone size quantifications were performed by digitally isolating R4 and R5 in Fiji and visualizing the 3D reconstructed organ in Imaris. A=anterior, P=posterior. DAPI (blue) labels nuclei.

(C-D) Cellular organization of *APC*^{-/-} clones. Cartoons (C) and images (D) show sagittal views of control tissue (top), a representative single-layered *APC*^{-/-} clone (middle), and a representative multilayered *APC*^{-/-} clone (bottom). Single-layered *APC*^{-/-} clones resemble control tissue. Multilayered clones creates adenomatous masses that protrude into the midgut lumen. In (D), immunostaining (red) for Coracle (Cor) and Discs large (Dlg) reveals cell outlines, GFP (green) labels *APC*^{-/-} clones, and DAPI (blue) labels all nuclei. Clones are 21 days post-induction.

(E) Saggital views of E-cad. E-cad::mTomato (red hot LUT) is expressed in control tissue (top panels) and in basally localized cells within multilayered APC^{-/-} clones (bottom panels; GFP, green) but is absent from supra-basal cells. Dotted line indicates the basement membrane.

(F) $APC^{-/-}$ clones progress from single-layered to multilayered over time. Graph shows the percent of all $APC^{-/-}$ clones that exhibit multilayering at 2, 5, 10, and 21 days after clone induction. Each data point represents one midgut. n = 3 midguts per timepoint; means ± S.D are shown.

(G-I) Comparison of single-layered and multi-layered $APC^{-/-}$ clones by clone size (G), percentages of cells per clone that express *rhomboid-lacZ* (H), and percentages of cells per clone that exhibit dpErk (I). Clones from n = 3 midguts per genotype; P values by Mann-Whitney U-test. Representative images shown in each image panel. For box-and-whisker plots, the boxes show median, 25th and 75th percentiles, and whiskers are minimum and maximum values. Scale bars, 50 µm.

Genetic systems to generate and manipulate tumors



Strategies for inducing gene expression in tumors



Figure S2. Three genetic systems to generate $APC^{-/-}$ clones and manipulate gene expression in either clones or non-clone cells. Related to Figures 1, 2, 3 and 4.

(A-C) In all three systems, all midgut cells are initially unlabeled and heterozygous for null alleles of *Apc1* (*Apc1*^{Q8}) and *Apc2* (*Apc2*^{G10}). Heat shock induction (two 30-min, 38.5°C heat shocks separated by an 8-min chill on ice) is used to activate expression of flp^{122} recombinase, which catalyzes recombination in mitotic stem cells to generate a daughter cell that is homozygous for both *Apc1*^{Q8} and *Apc2*^{G10} (*APC*-/-).

(A) Clone-autonomous labeling and manipulation. Schematic shows MARCM system to generate GFP-labeled $APC^{-/-}$ clones with concomitant genetic manipulation within clones. *Flp* recombination both generates an $APC^{-/-}$ daughter cell and eliminates *GAL80* specifically from that daughter. Loss of *GAL80* enables GAL4-driven expression of *UAS-GFP* and other *UAS*-transgenes (*UAS-gene X*) in the *APC*^{-/-} cell and its progeny.

(B) Clone non-autonomous ("non-clone cell") labeling. Schematic shows generation of unlabeled *APC*^{-/-} clones within a background of GFP-labeled, non-clone cells. All midgut cells initially express *ubi-GFP*. Heat-shock induction of *flp* recombinase produces an *APC*^{-/-} daughter cell that lacks *ubi-GFP*; the *APC*^{-/-} cell and any progeny it produces are thus unlabeled. Non-clone cells continue to express *ubi-GFP*.

(C) Clone non-autonomous ("non-clone cell") labeling and manipulation. Schematic shows the GeneSwitch 2326 system (also known as the "pLoser system" [S3]), which generates unlabeled $APC^{-/-}$ clones with concomitant labeling and manipulation of non-clone cells. Upon oral administration of RU486, *GeneSwitch2326* (*GS2326*) [S4] drives expression of *UAS*-transgenes (*UAS-gene X*) in midgut stem cells, enteroblasts, and enterocytes. Midgut cells initially express *ubi*-RFP and possess *GS2326*. Heat-shock induction of *flp* recombinase produces an $APC^{-/-}$ daughter cell that lacks *ubi-RFP* and *GS2326*. Non-clone cells, which continue to express *ubi-RFP*, are capable of RU486-inducible expression of *UAS*-transgenes, whereas unlabeled $APC^{-/-}$ cells are not. In all GeneSwitch experiments, RU486 was administered to both control and experimental cohorts.

(D-E) Experimental protocols for induction of *APC*^{-/-} clones and concomitant genetic manipulation.

(D) Clone-autonomous genetic manipulation using MARCM. Animals eclose at 25°C. Initially, all UAS-transgenes are silent due to ubiquitous expression of *tubGAL80*. At 1 day after eclosion, heat shock-induced *flp*¹²² generates $APC^{-/-}$ mutant stem cells that have permanently lost *tubGAL80*. Loss of *tubGAL80* enables *tubGAL4*-driven expression of UAS-GFP and other UAS-transgenes (UAS-geneX) within $APC^{-/-}$ stem cells and any $APC^{-/-}$ stem cell progeny that are produced during the subsequent 25°C chase. See also panel A.

(E) Clone non-autonomous ("non-clone cell" genetic manipulation using "pLoser" [S3]. Animals eclose at 25°C. Initially, *ubiRFP* is expressed in all cells, and all *UAS*-transgenes are silent because *GeneSwitch2326* (*GS2326*), which drives expression in enterocytes, enteroblasts, and stem cells, is inactive in the absence of RU486. At 1 day after eclosion, heat shock-induced *flp*¹²² generates *APC*^{-/-} mutant stem cells that have permanently lost both *ubi-RFP* and *GS2326* (*c.f.* panel C), while non-clone cells retain both *ubi-RFP* and *GS2326*. To activate expression of *UAS*-transgenes (*UAS-geneX*) in these RFP-expressing non-clone cells, RU486 is orally administered immediately after heat shock and throughout the subsequent 25°C chase. By contrast, the unlabeled *APC*^{-/-} stem cells and their progeny are unresponsive to RU486. In all experiments using the "pLoser" systemn, RU486 was administered to both control and experimental cohorts.



Figure S3. Effects of inhibiting apoptosis or JNK signaling on *rhomboid* expression, Erk activation, and tumor progression. Related to Figures 2 and 3.

(A) Positive control for immunostaining of apoptotic cells by anti-cleaved Caspase3 antibody. To induce apoptosis of midgut cells, the damaging agent bleomycin was administered orally. Substantially more Casp3⁺ cells are visible in bleomycin-treated midguts compared to untreated control midguts.

(B) Sample images of midguts analyzed for Figures 2D and 3B. The genetic schema in Figure S2B was used to generate either control clones (top) or $APC^{-/-}$ clones (bottom) in midguts containing *rhomboid-lacZ*. Clones are unmarked, and non-clone cells are marked with RFP (red in second panel from left). Midguts were immunostained for *rhomboid-lacZ* (anti- β -galactosidase antibody; green in left panel, inverted grayscale in right panel) and Casp3 (inverted grayscale in second panel from panel from right). In guts with control clones, most *rhomboid-lacZ*⁺ cells are Casp3⁺ (red arrowheads). In guts with $APC^{-/-}$ clones, most *rhomboid-lacZ*⁺ cells are Casp3⁻.

(C-F) Tumor autonomous activation of Erk decreases following p35-mediated inhibition of apoptosis in non-clone cells but not tumor cells. Representative images (C, E) and quantitation (D, F) of dpErk immunostaining in $APC^{-/-}$ clones. In (C, D), *p35* was expressed in GFP-marked $APC^{-/-}$ clones using the genetic schema in Figures S2A and S2D. In (E, F), *p35* was expressed in RFP-marked non-clone cells surrounding unmarked $APC^{-/-}$ clones using the genetic schema in Figures S2E. In (F), *p35* was expressed in RFP-marked non-clone cells surrounding unmarked $APC^{-/-}$ clones using the genetic schema in Figures S2E. In (F), *54* clones in the *p35* condition contain zero dpErk+ cells (0%).

(G-L) Tumor progression is reduced by inhibition of either apoptosis or JNK in nonclone cells but not tumor cells. Representative images (G, J) and quantitation of clone sizes (H, K) and multilayering (I, L). In (G-I), the genetic schema in Figures S2A and S2D was used to express the indicated transgenes in GFP-marked control or $APC^{-/-}$ clones. In (J-L), the genetic schema in Figures S2C and S2E was used to express the indicated transgenes in RFP-marked non-clone cells surrounding either control or $APC^{-/-}$ clones.

For (C-L), genetic manipulations within clones were performed as in Figures 1D and genetic manipulations in non-clone cells were performed as in Figure 3C; one of three independent experiments is shown. In (D, F, H, K), n = 3 midguts per genotype; *P* values by Mann-Whitney *U*-test. In (I, L), n = 4 midguts per genotype; *P* values by unpaired *t*-test. Representative images shown in all panels; clone boundaries are outlined. For box-and-whisker plots, the boxes show median, 25th and 75th percentiles, and whiskers are minimum and maximum values. Scale bars, 50 µm.



Figure S4. JNK and *rhomboid* hyper-activation are specifically associated with *APC*^{-/-} tumors. Related to Figure 4.

(A) Wide-field, representative images of midguts in Figure 4B show either control or $APC^{-/-}$ clones at 21 days post-induction. Clone boundaries are outlined in white (left panels) and in black (right panels). pJNK⁺ cells and *rhomboid-lacZ*⁺ non-clone cells localize to the vicinity of $APC^{-/-}$ clones. Scale bars, 50 µm.

(B) Distances between *rhomboid-lacZ*⁺ non-clone cells and the nearest $APC^{-/-}$ clone. Distances were measured from the center of each *rhomboid-lacZ*⁺ non-clone cell nucleus to the center of the closest nucleus within the nearest clone was measured. *n* = 344 *rhomboid-lacZ*⁺ cells pooled from 3 midguts.

(C-F) Baseline frequencies of JNK and *rhomboid* activation in $APC^{+/+}$ and $APC^{+/-}$ midguts without clone induction. (C) Midguts of genotypes used in the Figure S2B schema were harvested at 22 days post-eclosion without clone induction and immunostained for *rhomboid-lacZ* and pJNK. (D) pJNK⁺ cells are elevated in $APC^{+/--}$ midguts compared to $APC^{+/+}$ midguts but are 250-fold less abundant compared to $APC^{+/--}$ midguts that contain $APC^{-/-}$ clones (*c.f.* Figure 4C). (E) *rhomboid-lacZ*⁺ cells are comparable in $APC^{+/+}$ and $APC^{+/-}$ midguts and substantially less abundant compared to $APC^{+/-}$ midguts that contain $APC^{-/-}$ clones (*c.f.* Figure 4D). (F) Percentage of all *rhomboid*-lacZ⁺ midgut cells that are also pJNK⁺ is elevated in $APC^{+/-}$ midguts compared to $APC^{+/+}$ midguts but is markedly lower compared to $APC^{+/-}$ midguts that contain $APC^{-/-}$ clones (*c.f.* Figure 4E). In (**D-F**), each data point represents one midgut; *n* = 4 midguts per condition. *P* values by unpaired *t*-test. For box-and-whisker plots, the boxes show median, 25th and 75th percentiles, and whiskers are minimum and maximum values.

Figure	Panels	Genotype
Figure 1	1B-C	hsflp ¹²² , UAS-GFP; tubGAL4 / E-cad ^{mTomato} ; FRT82B tubGAL80 / TM6B
		hsflp ¹²² , UAS-GFP; tubGAL4 / E-cad ^{mTomato} ; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	1F-H	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-E-cad; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-E-cad ^{dCR4h} ; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-E-cad ^Δ JM; FRT82B tubGAL80 / FRT82B
		hsflp122, UAS-GFP; tubGAL4 / UAS-p120 RNAi; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-E-cad; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp122, UAS-GFP; tubGAL4 / UAS-E-cad ^{dCR4h} ; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-E-cad ^Δ JM; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp122, UAS-GFP; tubGAL4 / UAS-p120 RNAi; FRT82B tubGAL80 / FRT82B, APC2G10, APC1Q8
Figure 2	2B-D	hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B
		hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	2E-F	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	2G-I	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B
		hsflp122, UAS-GFP; tubGAL4 / UAS-egfr RNAi; FRT82B tubGAL80 / FRT82B
		hsflp122, UAS-GFP; tubGAL4 / UAS-rho RNAi; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-egfr RNAi; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp122, UAS-GFP; tubGAL4 / UAS-rho RNAi; FRT82B tubGAL80 / FRT82B, APC2G10, APC1Q8
Figure 3	3A-B	hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B
		hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	3D-F	hsflp ¹²² ; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; UAS-rho RNAi; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; UAS-E-cad; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; UAS-p120 RNAi; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; UAS-egfr RNAi; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² ; UAS-rho RNAi; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² ; UAS-E-cad; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² ; UAS-p120 RNAi; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² ; UAS-egfr RNAi; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
Figure 4	4B-E	hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	4F	hsflp ¹²² ; FRT82B, GS2326, ubi-RFP / FRT82B (reference cDNA)
	4F-H	hsflp ¹²² ; FRT82B, GSG2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² / UAS-bsk ^{DN} ; FRT82B, GSG2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
Figure S1	S1B	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S1D-E	hsflp ¹²² , UAS-GFP; tubGAL4 / E-cad ^{mTomato} ; FRT82B tubGAL80 / TM6B
		hsflp ¹²² , UAS-GFP; tubGAL4 / E-cad ^{mTomato} ; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S1F, H	hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S1G, I	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}

Figure S2	S2A, D	hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-X; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S2B	hsflp ¹²² ; FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S2C, E	hsflp ¹²² ; UAS-X; FRT82B, GSG2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
Figure S3	S3A-B	hsflp ¹²² ; rho-lacZ (rho ^{X81}), FRT82B, ubi-GFP / FRT82B
	S3B	hsflp ¹²² ; rho-lacZ (rho ^{X81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S3C-D	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-p35; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S3E-F	hsflp ¹²² ; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² ; UAS-p35; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S3G-I	hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP / UAS-bsk ^{DN} ; tubGAL4; FRT82B tubGAL80 / FRT82B
		hsflp122, UAS-GFP; tubGAL4 / UAS-p35; FRT82B tubGAL80 / FRT82B
		hsflp ¹²² , UAS-GFP; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² , UAS- GFP / UAS-bsk ^{DN} ; tubGAL4; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² , UAS-GFP; tubGAL4 / UAS-p35; FRT82B tubGAL80 / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S3J-L	hsflp ¹²² ; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² / UAS-bsk ^{DN} ; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; UAS-p35; FRT82B, GS2326, ubi-RFP / FRT82B
		hsflp ¹²² ; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² / UAS-bsk ^{DN} ; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
		hsflp ¹²² ; UAS-p35; FRT82B, GS2326, ubi-RFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
Figure S4	S4A	hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B
	S4A-B	hsflp ¹²² ; rho-lacZ (rho ^{X81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}
	S4D-F	hsflp ¹²² ; rho-lacZ (rho ^{x81}), FRT82B, ubi-GFP / FRT82B
		hsflp ¹²² ; rho-lacZ (rho ^{X81}), FRT82B, ubi-GFP / FRT82B, APC2 ^{G10} , APC1 ^{Q8}

Table S1. Experiment genotype by figure. Related to STAR Methods.

'GS2326' denotes the GeneSwitch driver, *P[Switch]GSG2326* [S3].

'UAS-X' generically denotes a UAS-driven transgene of interest (ex: UAS-E-cad).

		Control	clones	APC ^{-/-} clones	
Figure panel	Condition	Total clones	No. of guts	Total clones	No. of guts
Figure 1C	Single-layered	-	-	67	4
	Multi-layered	-	-	38	4
Figure 1G	Clones alone	90	3	79	3
	E-cad	88	3	79	3
	E-cad ^{dCR4h}	70	3	97	3
	E-cad [∆] _{JM}	70	3	80	4
	<i>p120</i> RNAi	68	3	116	3
Figure 2C	rho-lacZ	81	3	47	4
Figure 2F	dpERK	88	3	74	3
Figure 2H	Clones alone	79	3	74	3
	<i>egfr</i> RNAi	24	3	53	4
	<i>rho</i> RNAi	84	3	83	3
Figure 3E	Clones alone	75	3	65	4
	<i>egfr</i> RNAi	39	4	71	3
	E-cad	52	3	72	3
	<i>p120</i> RNAi	49	3	78	3
	<i>rho</i> RNAi	76	4	81	3
Figure 4G	Clones alone	-	-	26	3
	bsk ^{DN}	-	-	53	3
Figure S1G	Single-layered	-	-	69	-
	Multi-layered	-	-	31	-
Figure S1H	Single-layered	-	-	35	-
	Multi-layered	-	-	12	-
Figure S1I	Single-layered	-	-	46	-
	Multi-layered	-	-	28	-
Figure S3D	Clones alone	-	-	60	3
	p35	-	-	53	3
Figure S3F	Clones alone	-	-	29	3
	p35	-	-	64	3
Figure S3H	Clones alone	79	3	40	3
	p35	39	3	53	3
	bsk ^{DN}	60	3	48	3
Figure S3K	Clones alone	48	3	55	4
	p35	70	3	64	3
	bsk ^{DN}	79	3	53	3

Table S2. Clone numbers shown per figure panel. Related to STAR Methods.

One of three repetitions is shown for each experiment; numbers of clones per experiment vary between repetitions. For Figure 1C, both early- and late-stage tumors were quantified from the same midguts (n = 4).

Cond	ition	Cont	rol clones	APC ^{-/-} clones	
Expression	UAS	Median	% multilayering	Median	% multilayering
•		clone size	(mean ± SD)	clone size	(mean ± SD)
	No UAS	8.5	0 ± 0	37	41.4 ± 6.3
	E-cad	3	0 ± 0	3	7.1 ± 3.2
	E-cad ^{∆JM}	14	0 ± 0	25	39.0 ± 6.4
	E-cad ^{dCR4h}	10	0 ± 0	5	7.2 ± 2.8
In clone cells	<i>p120</i> RNAi	7	0 ± 0	6	6.0 ± 2.2
	<i>rho</i> RNAi	5	0 ± 0	13.5	13.3 ± 2.8
	<i>egfr</i> RNAi	2	0 ± 0	2	0 ± 0
	p35	5	0 ± 0	20	31.1 ± 9.2
	bsk ^{DN}	7.5	0 ± 0	20	29.5 ± 6.3
	No UAS	9	0 ± 0	37	33.0 ± 4.2
	E-cad	5	0 ± 0	7	9.8 ± 7.4
	<i>p120</i> RNAi	5	0 ± 0	7	11.8 ± 10.2
In non-clone	<i>rho</i> RNAi	6	0 ± 0	10	15.5 ± 5.8
Cells	<i>egfr</i> RNAi	10	0 ± 0	42	39.8 ± 1.7
	p35	4	0 ± 0	9.5	11.0 ± 7.0
	bsk ^{DN}	9	0 ± 0	12	13.0 ± 1.6

Table S3. Experimental values by condition. Related to STAR Methods.

Values from one of three repetitions is shown for each experiment.

Supplemental References

- S1. Liang, J., Balachandra, S., Ngo, S., and O'Brien, L.E. (2017). Feedback regulation of steady-state epithelial turnover and organ size. Nature *548*, 588-591.
- S2. Buchon, N., Osman, D., David, F.P., Fang, H.Y., Boquete, J.P., Deplancke, B., and Lemaitre, B. (2013). Morphological and molecular characterization of adult midgut compartmentalization in Drosophila. Cell Rep *3*, 1725-1738.
- S3. Suijkerbuijk, S.J., Kolahgar, G., Kucinski, I., and Piddini, E. (2016). Cell Competition Drives the Growth of Intestinal Adenomas in Drosophila. Curr Biol 26, 428-438.
- S4. Roman, G., Endo, K., Zong, L., and Davis, R.L. (2001). P[Switch], a system for spatial and temporal control of gene expression in Drosophila melanogaster. Proc Natl Acad Sci U S A *98*, 12602-12607.